Mycobacterium leprae causes leprosy, a chronic infectious disease. Hansen's disease is another name for leprosy. The skin, mucosal surfaces of the upper respiratory tract, peripheral nerves, and eyes are all affected. People of all ages, from infants to the elderly, can contract leprosy. Although the actual method of transmission is unknown, it is widely assumed that leprosy is transmitted from a leprosy patient to a healthy person. Delayed leprosy diagnosis can lead to major problems like muscle weakness, erectile dysfunction, kidney failure, blindness, and more. Avoiding contact with infected and untreated patients is the greatest strategy to avoid contracting leprosy. Leprosy is a treatable disease, and there are a variety of medications on the market to treat it. Multidrug Therapy (MDT), which involves the use of a mixture of medications, is one of the treatments for leprosy. For leprosy therapy, the World Health Organization suggests combining rifampicin, clofazimine, and dapsone medicines.
The Future of Leprosy Treatment Market
According to the World Health Organization (WHO), the number of leprosy cases documented in 2015 was 176,176, or 0.18 cases per 10,000 persons, from diverse locations (138 countries). The number of new instances demonstrates the disease's ability to spread over time. According to global statistics, 22 significant nations were responsible for 203,600 (96%) of new leprosy cases. The high occurrences prevalence serves as a reminder that some parts of the world have significant disease incidence and transmission rates. In the previous two decades, the World Health Organization estimates that roughly 16 million cases of leprosy have been treated. On a global basis, governing agencies and countries are attempting to eradicate the disease's presence. The Leprosy Treatment Market is predicted to increase at a significant rate throughout the forecast period (2016–2024) because of these factors.
Market Analysis for Leprosy Treatment
Due to the growing patient pool of leprosy in Asia-Pacific, the Leprosy Treatment Market is predicted to rise at a breakneck pace over the forecast period. According to the WHO, 176 instances per 10,000 persons were diagnosed with this disease in 2015. India is home to over 60% of the world's leprosy sufferers. As a result, India is a key global market for this disease's treatment. Because antibacterial medications are frequently prescribed by doctors for leprosy treatment, the antibacterial category is predicted to gain the most market share over the projection period. Dapsone, rifampin, clofazimine, ofloxacin, and minocycline are some of the most frequent antibacterial medications used to treat leprosy. Because of the increasing popularity of e-commerce around the world, internet pharmacies are the fastest-growing distribution channel.
Read More:
| https://bloggerstrive.blogspot.com/2021/12/forecast-trend-analysis-and-future-of.html |
https://www.coherentmarketinsights.com/ongoing-insight/leprosy-treatment-market-128
